Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release Bayer's ClariSpray Success Bodes Well for Innovus Pharmaceuticals' FlutiCare
Posted on: 27 Aug 16

REDONDO BEACH, CA--(Marketwired - Aug 25, 2016) -, a leading financial news and information portal offering free real time public company filing alerts, recently published an article highlighting the potential FDA approval of Innovus Pharmaceuticals' (OTCQB: INNV) FlutiCare™ in the nasal allergy market following the recent approval of Bayer AG's ClariSpray™.

Bayer AG expanded its allergy portfolio in the United States to include ClariSpray™, a 24-hour nasal spray to treat allergy symptoms, in April 2016. Though the two drugs contain different ingredients, the company was looking to play off of the already successful Claritin™ brand. Despite a weak allergy season in the United States, the company's Claritin™ division 'developed positively' during the second quarter 'due primarily' to the launch of the nasal spray, with revenue expanding by a currency-adjusted 11% to $178 million euros.

ClariSpray™ is an over-the-counter nasal spray that contains fluticasone propionate, which is the generic name of Glaxosmithkline plc's Flonase. The new product's success shouldn't come as a surprise to those following the nasal spray market. According to some sources, Glaxosmithkline's Flonase peaked at around $1.3 billion in sales, which places it clearly in the 'blockbuster' category of drugs. The company has only a handful of competitors in the market at the moment, which has created a great opportunity for Bayer to take advantage of the gap.

Currently, FlutiCare™'s fluticasone propionate is awaiting an ANDA decision from the FDA that's expected over the coming month or two. With the drug's robust safety and efficacy profile, Innovus doesn't expect to meet any resistance from the FDA when making the decision. Management has also already signed a manufacturing agreement for the supply of FlutiCare™ 60 and 120 spray bottles and plans to leverage its existing distribution network that reaches over 30,000 stores in the U.S.

To read the full article, please click here:

For more information, visit the company's website at or download our free Company Analysis.


Founded in 2004, provides free real time filing alerts to over 600,000 registered members and offers services to help public companies grow their audience of interested investors.


Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit:

Contact Information
Paul Archie

For more information:

Editor's Details

Mike Wood

Last updated on: 27/08/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.